131454-80-3

Basic information

• Product Name: 5-(broMoMethyl)quinoxaline
• Synonyms: 5-(broMoMethyl)quinoxaline
• CAS NO: 131454-80-3
• Molecular Formula: C₉H₇BrN₂
• Molecular Weight: 223.06928
• Mol File: 131454-80-3.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-(broMoMethyl)quinoxaline(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(broMoMethyl)quinoxaline(131454-80-3)
• EPA Substance Registry System: 5-(broMoMethyl)quinoxaline(131454-80-3)

Safety Data

• Hazardous Substances Data: 131454-80-3(Hazardous Substances Data)

Upstream product

• 13708-12-8 5-methylquinoxaline 
• 93-59-4 Perbenzoic acid 
• 77-48-5 1,3-dibromo-5,5-dimethylimidazolidine-2,4-dione 

Relevant articles and documents

Building blocks for cyclotriveratrylene-based coordination networks

The incorporation of three-fold symmetric organic host molecules into coordination polymers should allow for the construction of new and interesting network structures, capable of multiple inclusion behaviour. A range of new multi-dentate bridging ligands/molecular hosts have been prepared by appending nitrogen-containing heterocycles to either cyclotricatechylene, or cyclotriguaiacylene cores. These compounds were obtained in a single-step reaction from readily available precursors, with moderate to good yields, and characterised by a combination of NMR spectroscopy, mass spectrometry and elemental analysis. Two of the new compounds were characterised by X-ray crystallography, revealing different modes of self inclusion behaviour, which indicate the potential importance of π-donor stabilisation by CTV derivatives in host-guest chemistry.

Inhibition of the Cysteine Protease Human Cathepsin L by Triazine Nitriles: Amide???Heteroarene π-Stacking Interactions and Chalcogen Bonding in the S3 Pocket

We report an extensive “heteroarene scan” of triazine nitrile ligands of the cysteine protease human cathepsin L (hCatL) to investigate π-stacking on the peptide amide bond Gly67–Gly68 at the entrance of the S3 pocket. This heteroarene???peptide bond stacking was supported by a co-crystal structure of an imidazopyridine ligand with hCatL. Inhibitory constants (Ki) are strongly influenced by the diverse nature of the heterocycles and specific interactions with the local environment of the S3 pocket. Binding affinities vary by three orders of magnitude. All heteroaromatic ligands feature enhanced binding by comparison with hydrocarbon analogues. Predicted energetic contributions from the orientation of the local dipole moments of heteroarene and peptide bond could not be confirmed. Binding of benzothienyl (Ki=4 nm) and benzothiazolyl (Ki=17 nm) ligands was enhanced by intermolecular C?S???O=C interactions (chalcogen bonding) with the backbone C=O of Asn66 in the S3 pocket. The ligands were also tested for the related enzyme rhodesain.

PYRAZINE DERIVATIVES,PROCESS FOR MANUFACTURE AND USE THEREOF

Pyrazine derivatives of formula (I) and pharmaceutically acceptable salts thereof are disclosed, wherein the designation of R1, R2, R3 and R4 are provided herein. Syntheses for preparation of such compounds are disclosed. Methods of use of these compounds and pharmaceutical compositions containing them for treatment and/or prevention of diseases and for manufacture of medicaments are disclosed. These compounds and pharmaceutical compositions have antioxidative and thrombolytic effects, and thus can be used for the treatment and/or prevention of cerebral stroke caused by ischemia, and used for manufacture of medicaments for the treatment and/or prevention of nervous system diseases caused by excessive amount of radicals and/or thrombosis, infectious diseases, metabolic system diseases, cardiovascular and cerebrovascular diseases, and age-related degenerative diseases.